--Cleveland BioLabs is back in the race to develop an anti-radiation drug for the U.S. military. and I couldn't be happier. I know who we need on this name biobottom I was bad and didn't return an email I wonder if he's still out there...... Osiris nabbed the coveted contract and investors fled CBLI. But Cleveland BioLabs got back into the game last week when it won a developmental contract worth up to $8.9 million from the Defense Department to develop its Protectan drug as a way of treating soldiers who have been exposed to radiation. While the contract doesn't commit the government to buying any Protectan, it gives Cleveland BioLabs valuable funding to continue its research on the drug, which is in the testing stage and still needs to be approved for use in humans. What's big here is the " stockpiling angle " whatever drug is bought will be bought massively by governments and then of course they dwindle in potency over time... can you say REORDER! This is going to be a really great contract when it comes.... "I think we're in a good position to win." the CEO says! With Cleveland BioLabs' Protectan costing around $200 a dose, 1 million orders would mean roughly $200 million in sales. That would turn Cleveland BioLabs from a fledgling research company to a full-blown drug manufacturer in a hurry. Even better, from Cleveland BioLabs' perspective, is that the stockpiled doses eventually lose their effectiveness, which means ongoing sales to keep the supplies fresh. If the military market fully develops, if Homeland Security starts stockpiling doses for civilians, if Israel does the same, CEO Fonstein thinks Cleveland Bio- Labs could be looking at a market worth $500 million a year. >If Protectan works and if the drug wins approval for use from regulators. Fonstein is encouraged by recent test results, which showed that Protectan helped monkeys survive two-thirds of the time after they were exposed to lethal levels of radiation and were given the drug 48 hours after exposure. That was much better than the 25 percent survival rate among a control group. Those results, released publicly last week, weren't available when Cleveland BioLabs originally applied for the contract that ended up going to Osiris, whose drug has the disadvantage of costing about $10,000 a dose and can only be administered in clinical settings!!! hello $10 grand a pop! no wonder the gov is looking to CBLI, maybe we all should to.... Protectan can be administered by fellow soldiers on the battlefield. Cleveland BioLabs hopes to have Protectan ready for military use in less than three years, mainly because the approval standards for military use aren't as stringent as the ones used for medical use. That's a big investor heads up we don't need FDA approval for good pub here just ARMY purchases! Full-blown FDA approval will require additional testing beyond that required by the military. Of course there are other medical targets for the drug, but that seems a long ways off. For now, we have a cheaper product by a lot that new studdies have shown has some good numbers in mice. BRING ON THE HUMANS! Keep an eye on CBLI. ~stoney
AP article Drug Experiment Blocks Radiation Damage By LAURAN NEERGAARD WASHINGTON (AP) â Scientists mimicked one of cancer's sneaky tricks to create a drug that promises to prevent a serious side effect of cancer treatment â radiation damage â or offer an antidote during a nuclear emergency. A single dose of the experimental drug protected both mice and monkeys from what should have been lethal doses of radiation, researchers report in Friday's edition of the journal Science. A study to see if the compound is safe in people could begin as early as this summer. It's still early-stage research, and other efforts to create radiation protectants haven't yet panned out. But specialists are closely watching the work â and the government is helping to fund it â because it's a new approach to protecting the body's most radiation-sensitive tissues from being blasted. "It has important implications for radiation exposure," said Dr. David Kirsch, a Duke University radiation oncologist who wasn't involved in the drug research. Radiation is a powerful tool to destroy cancer cells. But certain healthy tissues are especially sensitive to it, too, particularly the bone marrow and gastrointestinal tract. That vulnerability can limit how much radiation physicians are able to give cancer patients. And when it comes to radiation emergencies, such as the Chernobyl accident, full-body exposure to high doses can cause an extremely lethal "GI syndrome" that has no treatment. It turns out that radiation doesn't kill healthy cells in the same way that it kills cancer cells. Instead, bone marrow and GI cells overreact to what should be reparable damage and commit suicide, through a well-known process called apoptosis, explained Andrei Gudkov of the Roswell Park Cancer Institute, who led development of the drug code-named CBLB502. Learning that was the "eureka" moment, Gudkov said. Apoptosis is the body's way of stopping defective cells, with damaged genes, from spreading. Tumors grow because cancer cells block apoptosis in various ways, including by activating a normally dormant cell-signaling pathway called "nuclear factor-KappaB" or NFKB. Gudkov's team decided to try activating that same pathway in healthy tissue, to see if it could keep radiation-blasted cells from triggering their suicide program. "We imitated a tumor trick," is how Gudkov puts it. The team knew that flagellin, a protein from normal gut bacteria, can wake up NFKB. So they created a drug based on that natural protein. In a series of experiments, they injected the drug into mice and rhesus monkeys anywhere from 15 minutes to an hour before exposing the animals to lethal doses of full-body radiation. The drug dramatically improved the animals' survival, protecting against both bone marrow and GI destruction, with no obvious side effects. The drug also improved survival when given to mice an hour after fairly high radiation doses, although not the very highest. A final experiment showed the drug didn't block radiation from treating the tumors of the mice even as it protected their healthy tissue. Gudkov founded a company called Cleveland Biolabs Inc. that is working to bring the drug to market â both for use in cancer radiotherapy and for biodefense. The Defense Department and other government agencies are helping to fund the research. "For many years, the radiation oncology community has tried to develop radioprotectants" based on different biology, said Dr. Richard Kolesnick of Memorial Sloan-Kettering Cancer Center, who has long researched radiation's effects. "This new information on the mechanisms of tissue damage to the GI tract has resulted in a potentially important new drug to prevent this lethal GI syndrome after a radiation accident or potential terrorist attack." Duke's Kirsch agreed that the animal experiments suggest the drug has potential for radiation emergencies. But he stressed that a cancer role is less clear, because cancer patients' biggest trouble comes with late-stage radiation effects, the cumulative buildup of damage. "That's what's dose-limiting," he said.
beautiful 25 cent opening gap and more after that. Do you guys mind the info the day before the s hits? Or do you prefer after the fact stuff???? Damn! ~ stoney I'll take 13% overnight any day at any bank! Cleveland BioLabs, Inc. (Public, NASDAQ:CBLI) - Add to Portfolio - Discuss CBLI Find more results for cbli 4.76 +0.56 (13.33%)
Folks this trade has gone nuts on us- upto $5.50; we have another 11% gain today- 25% or so in 2 days, now and of course the company has to go and get tricky announcing a hype type rush conference call to fill everyone in on the big news at the co... well we already did that here at ET, this is a sell the news event coming up as yahoo message board investors get involved. I'm stepping off... though in a terrorist crisis I WOULD INJECT MYSELF WITH THEIR PRODUCT! that's how strongly I believe in CBLI. ~ stoney
Stoney, Nice going on CBLI purchase, its still going rocketing up in price... Is CBLI going to be a longer term hold or just a trade on the news?